Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)
NCT ID: NCT01797419
Last Updated: 2013-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2013-05-31
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
GS-5806
Single dose, oral liquid, .5 mL/kg
GS-5806
Single dose, oral liquid, .5 mL/kg
Placebo
Single dose, oral liquid, .5 mL/kg
Placebo
Single dose, oral liquid, .5 mL/kg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GS-5806
Single dose, oral liquid, .5 mL/kg
Placebo
Single dose, oral liquid, .5 mL/kg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening
Exclusion Criteria
* Required ventilation or admission to any pediatric Intensive Care Unit
* Inadequate organ function
1 Hour
24 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Sly, MD
Role: PRINCIPAL_INVESTIGATOR
Queensland Children's Medical Research Unit, Herston, AUS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geelong Hospital
Geelong, Victoria, Australia
Monash Medical Center
Clayton, , Australia
Queensland Children's Medical Research Unit
Herston, , Australia
Royal Hobart Hospital
Hobart, , Australia
Women's and Children's Hospital Adelaide
North Adelaide, , Australia
Royal Children's Hospital
Parkville, , Australia
Sydney Children's Hospital
Randwick, , Australia
Princess Margaret Hospital for Children
Subiaco, , Australia
Westmead Children's Hospital
Westmead, , Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-US-218-0104
Identifier Type: -
Identifier Source: org_study_id